How Adoptive Cell Therapy Works
TUMOR INFILTRATING LYMPHOCYTE (TIL) therapy is derived from a patient’s own immune cells called lymphocytes that that have come to the site of tumor to kill the tumor. TIL therapy consists of expanded and rejuvenated TIL that was extracted from the tumor. To learn more, please visit our Iovance TIL technology page here.
NOW ENROLLING
Current Clinical Trials
PHYSICIANS: Learn more on ClinicalTrials.gov, including eligibility criteria, locations and contacts.
C-145-04: Metastatic Cervical Cancer
A Phase 2, Multicenter study to Assess the Safety and Efficacy of Autologous Tumor Infiltrating Lymphocytes (Lifileucel, formerly LN-145) for Treatment of Patients with Metastatic Cervical Cancer.
View
IOV-LUN-202: Metastatic Non-Small Cell Lung Cancer
A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) for Treatment of Patients with Metastatic Non-Small-Cell Lung Cancer (NSCLC)
View
IOV-COM-202: Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (Lifileucel or LN-145/LN-145-S1) in Patients with Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma (HNSCC), and Non-Small Cell Lung Cancer (NSCLC)
View
IOV-CLL-01: Polyclonal Blood-Based T Cell Therapy for Blood Cancers
A Phase 1/2 Study of Autologous Peripheral Blood Lymphocytes (PBLs) in the Treatment of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.
View